Patients with β -TM exhibit a number of immunological abnormalities, the most significant of which is the impairment of neutrophil and macrophage phagocytic and killing capabilities as well as the release of certain cytokines. our study aims to assess the levels of serum IL-33, zinc, copper, and ferritin in patients with thalassemia who are dependent on transfusions and receiving iron chelation therapy. the case-control study was performed on 180 persons (120 of β -TM patients with ages ranging from 5 to 20 years and 60 of control group) of similar age and sex were also examined as a control group. By using spectrophotometry, the levels of serum iron, zinc, and copper were determined, and serum IL-33 and ferritin levels were measured by the Enzyme-Linked Immunosorbent Assay (ELISA) method. An independent sample t-test was utilized for statistical analysis. The mean serum zinc, transferrin, TIBC and UIBC level was significantly (p<0.01) lower and serumIL-33, ferritin, iron and TS% level was significantly (p<0.01) higher in β -TM patients compared to control group. No significant difference in serum Cu between patients and control.  Furthermore, a statistically significant positive connection was found between serum IL-33 levels and age, BMI, ferritin, TS%, Fe, and Cu (r = (0.701**), (0.457**), (0.649**), (0.627**), (0.488**), and (0.624**). also, serum levels IL-33 were found to be negatively correlated with TIBC, UIBC, Transferrin, and Zn, r = (-0.549**), (-0.643**), (-0.549**) and (-0.486**) respectively. In summary, we find that  IL-33 is a novel inflammatory marker of  the patients with β-TM.